{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:23:39Z","timestamp":1715991819835},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,12,17]],"date-time":"2016-12-17T00:00:00Z","timestamp":1481932800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical University of Lublin, Poland"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathol. Oncol. Res."],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s12253-016-0156-4","type":"journal-article","created":{"date-parts":[[2016,12,17]],"date-time":"2016-12-17T08:46:07Z","timestamp":1481964367000},"page":"607-614","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Polymorphisms of Genes Encoding Multidrug Resistance Proteins as a Predictive Factor for Second-Line Docetaxel Therapy in Advanced Non-small Cell Lung Cancer"],"prefix":"10.1007","volume":"23","author":[{"given":"Micha\u0142","family":"Szczyrek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rados\u0142aw","family":"Mlak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawe\u0142","family":"Krawczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamila","family":"Wojas-Krawczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Powr\u00f3zek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aneta","family":"Szudy-Szczyrek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Zwolak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jadwiga","family":"Daniluk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janusz","family":"Milanowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,17]]},"reference":[{"key":"156_CR1","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","volume":"18","author":"FA Shepherd","year":"2000","unstructured":"Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O\u2019Rourke M et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non\u2013small-cell lung cancer previously treated with patinum-based chemotherapy. J Clin Oncol 18:2095\u20132103","journal-title":"J Clin Oncol"},{"issue":"12","key":"156_CR2","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1200\/JCO.2000.18.12.2354","volume":"18","author":"FV Fossella","year":"2000","unstructured":"Fossella FV, De Vore R, Kerr RN, Crawford J, Natale RR, Dunphy F et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group. J Clin Oncol 18(12):2354\u20132362","journal-title":"J Clin Oncol"},{"issue":"supl 1","key":"156_CR3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1634\/theoncologist.13-S1-28","volume":"13","author":"TE Stinchcombe","year":"2008","unstructured":"Stinchcombe TE, Soci\u0144ski MA (2008) Consideration for second line therapy of non-small cell lung cancer. Oncologist 13(supl 1):28\u201336","journal-title":"Oncologist"},{"key":"156_CR4","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","volume":"1","author":"N Hanna","year":"2004","unstructured":"Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 1:1589\u20131597","journal-title":"J Clin Oncol"},{"issue":"3","key":"156_CR5","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/annonc\/mdl454","volume":"18","author":"GJ Weiss","year":"2007","unstructured":"Weiss GJ, Rosell R, Fossella F, Perry M, Stahel R, Barata F et al (2007) The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 18(3):453\u2013460","journal-title":"Ann Oncol"},{"issue":"6","key":"156_CR6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3816\/CLC.2006.n.024","volume":"7","author":"C Tibaldi","year":"2006","unstructured":"Tibaldi C, Bernardini I, Chella A, Russo F, Vasile E, Malventi M et al (2006) Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small-cell lung cancer. Clin Lung Cancer 7(6):401\u2013405","journal-title":"Clin Lung Cancer"},{"issue":"4","key":"156_CR7","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00280-014-2522-9","volume":"74","author":"EO Macedo-P\u00e9rez","year":"2014","unstructured":"Macedo-P\u00e9rez EO, Morales-Oyarvide V, Mendoza-Garc\u00eda VO, Dorantes-Gallareta Y, Flores-Estrada D, Arrieta O (2014) Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 74(4):681\u2013690","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"156_CR8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S1470-2045(08)70029-9","volume":"9","author":"P S\u00e8ve","year":"2008","unstructured":"S\u00e8ve P, Dumontet CI (2008) Class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 9(2):168\u2013175","journal-title":"Lancet Oncol"},{"issue":"1","key":"156_CR9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.lungcan.2012.01.005","volume":"77","author":"HL Zhang","year":"2012","unstructured":"Zhang HL, Ruan L, Zheng LM, Whyte D, Tzeng CM, Zhou XW (2012) Association between class III \u03b2-tubulin expression and response to paclitaxel\/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis. Lung Cancer 77(1):9\u201315","journal-title":"Lung Cancer"},{"issue":"3","key":"156_CR10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10147-012-0386-8","volume":"18","author":"K Kaira","year":"2013","unstructured":"Kaira K, Takahashi T, Murakami H, Shukuya T, Kenmotsu H, Ono A et al (2013) The role of \u03b2III-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy. Int J Clin Oncol 18(3):371\u2013379","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"156_CR11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/sj.tpj.6500403","volume":"7","author":"S Haenisch","year":"2007","unstructured":"Haenisch S, Zimmermann U, Dazert E, Wruck CJ, Dazert P, Siegmund W, Kroemer HK, Warzok RW, Cascorbi I (2007) Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J 7(1):56\u201365","journal-title":"Pharmacogenomics J"},{"key":"156_CR12","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.21214","volume":"44","author":"Y Meier","year":"2006","unstructured":"Meier Y, Pauli-Magnus C, Zanger UM, Klein K, Schaeffeler E, Nussler AK, Nussler N, Eichelbaum M, Meier PJ, Stieger B (2006) Interindividual variability of canalicular ATP-binding cassette (ABC)\u2013transporter expression in human liver. Hepatology 44:62\u201374","journal-title":"Hepatology"},{"issue":"8","key":"156_CR13","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdh319","volume":"15","author":"D Isla","year":"2004","unstructured":"Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M et al (2004) Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15(8):1194\u20131203","journal-title":"Ann Oncol"},{"issue":"5","key":"156_CR14","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/j.1349-7006.2008.00765.x","volume":"99","author":"K Kiyotani","year":"2008","unstructured":"Kiyotani K, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y (2008) Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci 99(5):967\u2013972","journal-title":"Cancer Sci"},{"key":"156_CR15","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1002\/ijc.27567","volume":"131","author":"D Campa","year":"2012","unstructured":"Campa D, Muller P, Edler L, Knoefel L, Barale R, Heussel CP, Thomas M, Canzian F, Risch AA (2012) Comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis. Int J Cancer 131:2920\u20132928","journal-title":"Int J Cancer"},{"issue":"1","key":"156_CR16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/FPC.0b013e32835b16d8","volume":"23","author":"LD Lewis","year":"2013","unstructured":"Lewis LD, Miller AA, Owzar K, Bies RR, Markova S, Jiang C et al (2013) The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805. Pharmacogenet Genomics 23(1):29\u201333","journal-title":"Pharmacogenet Genomics"}],"container-title":["Pathology & Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12253-016-0156-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-016-0156-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-016-0156-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,30]],"date-time":"2017-05-30T02:33:44Z","timestamp":1496111624000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12253-016-0156-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,17]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["156"],"URL":"https:\/\/doi.org\/10.1007\/s12253-016-0156-4","relation":{},"ISSN":["1219-4956","1532-2807"],"issn-type":[{"value":"1219-4956","type":"print"},{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,17]]}}}